MULTISYN

Multimodal Imaging of rare Synucleinopathies

 Coordinatore EBERHARD KARLS UNIVERSITAET TUEBINGEN 

 Organization address address: GESCHWISTER-SCHOLL-PLATZ
city: TUEBINGEN
postcode: 72074

contact info
Titolo: Dr.
Nome: Holm
Cognome: Graessner
Email: send email
Telefono: +49 70712985944
Fax: +49 70712925061

 Nazionalità Coordinatore Germany [DE]
 Totale costo 7˙865˙514 €
 EC contributo 5˙999˙998 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2013-INNOVATION-1
 Funding Scheme CP-FP
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-10-01   -   2018-09-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    EBERHARD KARLS UNIVERSITAET TUEBINGEN

 Organization address address: GESCHWISTER-SCHOLL-PLATZ
city: TUEBINGEN
postcode: 72074

contact info
Titolo: Dr.
Nome: Holm
Cognome: Graessner
Email: send email
Telefono: +49 70712985944
Fax: +49 70712925061

DE (TUEBINGEN) coordinator 2˙184˙148.15
2    LUNDS UNIVERSITET

 Organization address address: Paradisgatan 5c
city: LUND
postcode: 22100

contact info
Titolo: Prof.
Nome: Deniz
Cognome: Kirik
Email: send email
Telefono: +46 2220564
Fax: +46 2223436

SE (LUND) participant 848˙451.00
3    MODAG GmbH

 Organization address address: MIKROFORUM RING 3
city: WENDELSHEIM
postcode: 55234

contact info
Titolo: Prof.
Nome: Christian
Cognome: Griesinger
Email: send email
Telefono: +49 551 2012201
Fax: +49 551 2012202

DE (WENDELSHEIM) participant 784˙999.60
4    AFFIRIS AG

 Organization address address: KARL FARKAS GASSE 22
city: WIEN
postcode: 1030

contact info
Titolo: Prof.
Nome: Achim
Cognome: Schneeberger
Email: send email
Telefono: +43 17981575300
Fax: +43 17981575311

AT (WIEN) participant 702˙249.25
5    MEDIZINISCHE UNIVERSITAET INNSBRUCK

 Organization address address: Christoph-Probst Platz 1
city: INNSBRUCK
postcode: 6020

contact info
Titolo: Dr.
Nome: Wolfram
Cognome: Rieneck
Email: send email
Telefono: 43512900000000
Fax: 43512900000000

AT (INNSBRUCK) participant 537˙410.00
6    PMOD TECHNOLOGIES GMBH

 Organization address address: RUTISTRASSE 20A
city: ADLISWIL
postcode: 8134

contact info
Titolo: Dr.
Nome: Cyrill
Cognome: Burger
Email: send email
Telefono: +41 443504600
Fax: +41 443504601

CH (ADLISWIL) participant 378˙500.00
7    AARHUS UNIVERSITET

 Organization address address: Nordre Ringgade 1
city: AARHUS C
postcode: 8000

contact info
Titolo: Mr.
Nome: Thomas
Cognome: Tandskov Dissing
Email: send email
Telefono: +45 23357522

DK (AARHUS C) participant 321˙240.00
8    "BIOMEDICAL RESEARCH FOUNDATION, ACADEMY OF ATHENS"

 Organization address address: Soranou Efesiou 4
city: ATHENS
postcode: 11527

contact info
Titolo: Mr.
Nome: Dimitrios
Cognome: Raptis
Email: send email
Telefono: +30 2106597574
Fax: +30 2106597571

EL (ATHENS) participant 243˙000.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

neuroimaging    imaging    mri    diseases    misfolded    structural    algorithm    alpha    causative    multimodal    therapeutic    ndd    syn    synuclein    progress    protein    ligand    caused    disease    clinical    pathogenesis    aggregation    functional    pet    trials    treatment    models    animal    molecular   

 Obiettivo del progetto (Objective)

'Despite remarkable progress in the understanding of the molecular pathogenesis of neurodegenerative diseases (NDD), no causative or disease-modifying treatment is currently available. Aggregation of misfolded proteins are thought to play a crucial role in the pathogenesis, but attempts to exploit this knowledge for novel treatments have not been successful. Also, pathogenetically relevant biomarkers of protein aggregation are lacking. In order to overcome this critical road-block, we have assembled an interdisciplinary consortium, consisting of world-leading experts in structural biology and ligand development, multimodal neuroimaging, animal models and clinical trials to develop a novel imaging system for combined simultaneous molecular and functional imaging (PET-MRI/fMRI) for two rare diseases caused by excessive accumulation of misfolded alpha-synuclein (αSYN), multiple systems atrophy (MSA) and parkinsonism caused by mutations in the alpha-synuclein gene (SNCA), which will serve as proof-of-principle models for the more common and heterogeneous NDD. With this technology we will pioneer the monitoring of protein aggregation as a biomarker for therapeutic effects in the framework of individualized causative treatment. The central aspects of the work-flow including ligand design, software development and drug trials will be driven by three highly specialized SMEs, while translation to animal models and clinical use will be implemented by top academic centers. The groundbreaking progress will include: 1. Establish a multimodal imaging algorithm based on a new PET tracer and embracing structural and functional MRI methods to yield an αSYN specific tool 2. Test this multimodal, molecular neuroimaging algorithm in animal models with regard to its potential for diagnosis, mirroring the natural disease course and response to therapy 3. Translate the algorithm including the therapeutic modality (i.e. immunotherapy with PD01, NCT01568099) to the clinical setting.'

Altri progetti dello stesso programma (FP7-HEALTH)

PATHCO (2012)

"Pathogen COinfection: HIV, Tuberculosis, Malaria and Hepatitis C virus"

Read More  

SICA-HF (2009)

Studies Investigating Co-morbidities Aggravating Heart Failure

Read More  

SCHIZDX (2008)

"Developing minimally invasive, tools and technologies for high throughput, low cost molecular assays for the early diagnosis of schizophrenia and other psychiatric disorders"

Read More